EP1453468A4 - Method of vaccinating a human patient to prevent metastatic tumors - Google Patents

Method of vaccinating a human patient to prevent metastatic tumors

Info

Publication number
EP1453468A4
EP1453468A4 EP02778802A EP02778802A EP1453468A4 EP 1453468 A4 EP1453468 A4 EP 1453468A4 EP 02778802 A EP02778802 A EP 02778802A EP 02778802 A EP02778802 A EP 02778802A EP 1453468 A4 EP1453468 A4 EP 1453468A4
Authority
EP
European Patent Office
Prior art keywords
vaccinating
human patient
metastatic tumors
prevent metastatic
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02778802A
Other languages
German (de)
French (fr)
Other versions
EP1453468A2 (en
Inventor
Ning Y Yu
Jian-Min Lin
Robert J Tressler
Richard E Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of EP1453468A2 publication Critical patent/EP1453468A2/en
Publication of EP1453468A4 publication Critical patent/EP1453468A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP02778802A 2001-11-09 2002-11-08 Method of vaccinating a human patient to prevent metastatic tumors Withdrawn EP1453468A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33798401P 2001-11-09 2001-11-09
US337984P 2001-11-09
PCT/US2002/035957 WO2003041645A2 (en) 2001-11-09 2002-11-08 Method of vaccinating a human patient to prevent metastatic tumors

Publications (2)

Publication Number Publication Date
EP1453468A2 EP1453468A2 (en) 2004-09-08
EP1453468A4 true EP1453468A4 (en) 2005-11-23

Family

ID=23322894

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02778802A Withdrawn EP1453468A4 (en) 2001-11-09 2002-11-08 Method of vaccinating a human patient to prevent metastatic tumors

Country Status (3)

Country Link
EP (1) EP1453468A4 (en)
AU (1) AU2002340439A1 (en)
WO (1) WO2003041645A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (en) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 How to treat anxiety disorders, headache disorders and eating disorders with psilocybin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017901A1 (en) * 1993-12-29 1995-07-06 Matrix Pharmaceutical, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017901A1 (en) * 1993-12-29 1995-07-06 Matrix Pharmaceutical, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BURRIS III H A ET AL: "INTRATUMORAL CISPLATIN/EPINEPHRINE-INJECTABLE GEL AS A PALLIATIVE TREATMENT FOR ACCESSIBLE SOLID TUMORS: A MULTICENTER PILOT STUDY", OTOLARYNGOLOGY AND HEAD AND NECK SURGERY, ROCHESTER, US, vol. 118, no. 4, April 1998 (1998-04-01), pages 496 - 503, XP000972300, ISSN: 0194-5998 *
CASTRO MICHAEL P; VANAUKEN JEAN; SPENCER-CISEK PATRICIA; LEGHA SEWA; SPONZO ROBERT W: "Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma. A case report and review of the literature", CANCER, vol. 85, no. 5, 1 March 1999 (1999-03-01), pages 1055 - 1059, XP002346834 *
DUVILLARD C ET AL: "EPINEPHRINE ENHANCES PENETRATION AND ANTI-CANCER ACTIVITY OF LOCAL CISPLANTIN ON RAT SUB-CUTANEOUS AND PERITONEAL TUMORS", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 81, no. 5, 1999, pages 779 - 784, XP000972333, ISSN: 0020-7136 *
GENNE PHILIPPE; DUCHAMP OLIVIER; SAINT-GENEZ FANNY; BISSON JEAN-FRANCOIS; WEI MING; POUPON MARIE-FRANCE; CHAUFFERT BRUNO: "In vivo screening of anticancer agents by intratumor (IT) treatment of human glioma in combination with epinephrine (EP)", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 42, March 2001 (2001-03-01), pages 480, XP008053028 *
MALHOTRA HARINDER; PLOSKER GREG L: "Cisplatin/epinephrine injectable gel", DRUGS AND AGING, vol. 18, no. 10, October 2001 (2001-10-01), pages 787 - 793, XP008053018 *
ORATZ RUTH: "Intratumoral chemotherapy with cisplatin/epinephrine injectable gel for treatment of advanced solid tumors", CANCER INVESTIGATION, vol. 17, no. Suppl.1, 1999, pages 87 - 88, XP008053020 *
PAPADIMITRIOU C A, SARRIS K, MOULOPOULOS L A, FOUNTZILAS G, ANAGNOSTOPOULOS A, VOULGARIS Z, GIKA D, GIANNAKOULIS N, DIAKOMANOLIS E: "Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix", JOURNAL OF CLINICAL ONCOLOGY, vol. 17, no. 3, March 1999 (1999-03-01), pages 761 - 766, XP002346833 *
PARRA H S ET AL: "Combination chemotherapy with Cisplatin (CDDP) and Adriamycin (ADM) plus immunotherapy with interferon (IFN) alfa-2b in malignant pleural mesothelioma (MPM): results of a phase II trial of the Italian Group on Rare Tumors (GITR) and Italian Lung Cancer Task Force (FONICAP)", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 35, September 1999 (1999-09-01), pages S257, XP004384935, ISSN: 0959-8049 *
SMITH JILL P; STOCK ELIZABETH; ORENBERG ELAINE K; YU NING Y; KANEKAL SARATHCHANDRA; BROWN DENNIS M: "Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts", ANTI-CANCER DRUGS, vol. 6, no. 6, 1995, pages 717 - 726, XP008053019 *

Also Published As

Publication number Publication date
WO2003041645A2 (en) 2003-05-22
WO2003041645A3 (en) 2003-07-24
AU2002340439A1 (en) 2003-05-26
EP1453468A2 (en) 2004-09-08

Similar Documents

Publication Publication Date Title
EP1469812A4 (en) Oral insulin therapy
HK1055752A1 (en) Surface treatment of medical device
EP1456910A4 (en) Invasive therapeutic probe
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
HK1116339A1 (en) Methods of administering epothilone analogs for the treatment of cancer
AU7434101A (en) Treatment of bone diseases
GB0204525D0 (en) Medical therapy apparatus
IL160998A0 (en) Human tissue factor antibodies
AU2003271021A8 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
GB0118383D0 (en) Therapeutic methods
IL176356A0 (en) Effervescent preparation of a basic medical substance
EP1495717A4 (en) Method for diagnosis of human organism
PL350850A1 (en) Method of providing cosmetic/medical therapy
HRP20030677A2 (en) Methods of administering epothilone analogs for the treatment of cancer
EP1453468A4 (en) Method of vaccinating a human patient to prevent metastatic tumors
AU2003287016A8 (en) Human sarcoma-associated antigens
IL155819A0 (en) Methods of treatment comprising administration of substance p
GB0023599D0 (en) Non-invasive method for determining human photodermatoogical skin-types
GB0105606D0 (en) Immunogens and vaccines and their preparation and use
EP1411354A4 (en) Method of detecting skin stimulation effect
HK1054946A1 (en) A non-invasive method of isolation of human dna
EP1306070A4 (en) Method for massaging human skin
IL142480A0 (en) Tissue growth stimulating system
GB2383947B (en) Medical apparatus for relief of pain
AU2002367463A8 (en) Novel p53bp2 compounds for therapy and diagnosis and methods for using same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040608

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7A 61K 33/24 B

Ipc: 7A 61K 31/555 B

Ipc: 7A 61K 31/282 A

A4 Supplementary search report drawn up and despatched

Effective date: 20051010

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051214